Results 71 to 80 of about 51,359 (249)
TIPE1m NPs nanoparticles restore TIPE1 expression, promote RAB7A ubiquitination and degradation, suppress autophagic flux, and resensitize paclitaxel‐resistant triple‐negative breast cancer to therapy. ABSTRACT Acquired paclitaxel (PTX) resistance remains a major obstacle in triple‐negative breast cancer (TNBC) treatment.
Wei Hu +9 more
wiley +1 more source
Advances in Single-Cell Sequencing Technology and Its Applications in Triple-Negative Breast Cancer
Meng Li, Tingting Yan, Miaozhou Wang, Yanqiu Cai, Yingyuan Wei Graduate School of Qinghai University, Qinghai University, Xining, Qinghai Province, People’s Republic of ChinaCorrespondence: Miaozhou Wang, Email wangmiaozhou@163.comAbstract: Triple ...
Li M, Yan T, Wang M, Cai Y, Wei Y
doaj
CircZNF148 stabilizes HK1 through deubiquitinase recruitment, thereby enhancing glycolysis and lactate production. Elevated lactate promotes PD‑L1 lactylation and membrane accumulation while suppressing CD8+ T‐cell cytotoxicity, collectively facilitating immune evasion and malignant progression in TNBC.
Yuhan Jin +17 more
wiley +1 more source
The therapeutic role of γδT cells in TNBC
Triple-negative breast cancer (TNBC) is a subtype of breast cancer that presents significant therapeutic challenges due to the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression.
Wenjing Li +6 more
openaire +3 more sources
Whole‐blood biomimetic engineering transforms liquid metal nanoparticles into a tripartite immunotherapeutic platform that orchestrates regulatory T‐cell depletion, photothermal‐induced immunogenic cell death, and activation of the stimulator of interferon genes pathway.
Nina Sang, Eijiro Miyako
wiley +1 more source
Insights into the Prognostic Value of Small Nucleolar RNA U81 and SNORA7B in Breast Cancer
Jun Zhou,1 Xuan Zhu,2 Jingpei Long1 1Department of Breast Surgery, The Women’s Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, People’s Republic of China; 2Department of Radiotherapy, The First Affiliated Hospital of Zhejiang ...
Zhou J, Zhu X, Long J
doaj
Engineering Antibodies into Targeted Chimeras: From Recognition Modules to Programmable Degraders
Antibody can be engineered into diverse lysosome‐targeting chimeras that convert target recognition into active degradation. By coupling antibody binding with recruited receptors, encoded domains, conjugated ligands, or nanoparticle scaffolds, these antibody‐associated targeted chimeras (AbTACs) platforms direct extracellular and membrane proteins ...
Kaige Chen, Quanyin Hu
wiley +1 more source
Ibnu Purwanto,1,* Benedreky Leo,2,* Susanna Hilda Hutajulu,1 Johan Kurnianda,1 Kartika Widayati Taroeno-Hariadi,1 Mardiah Suci Hardianti,1 Amanda Dania Satiti,1 Ery Kus Dwianingsih,3 Didik Setyo Heriyanto,3 Irianiwati Widodo,3 Teguh Aryandono4 ...
Purwanto I +10 more
doaj
Overcoming Drug Resistance by Paclitaxel Resistance in Triple‐Negative Breast Cancer
In the murine triple‐negative breast cancer (TNBC) model, chemotherapy effectively increases tumor neoantigen burden (TNB). Here, the study constructs a liposomal nanovaccine using antigens derived from in vitro chemotherapy‐treated paclitaxel‐resistant TNBC 4T1 cells.
Bo Chen +10 more
wiley +1 more source
The search for a TNBC vaccine: the guardian vaccine
Nearly 20 million people are diagnosed with cancer each year with breast cancer being the most common among women. Triple negative breast cancer (TNBC), defined by its no/low expression of ER and PR and lack of amplification of HER2, makes up 15-20% of all breast cancer cases. While patients overall have a higher response to chemotherapy, this subgroup
Cory Fines +2 more
openaire +3 more sources

